<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334318</url>
  </required_header>
  <id_info>
    <org_study_id>2018PG-T1D014</org_study_id>
    <nct_id>NCT03334318</nct_id>
  </id_info>
  <brief_title>PERL Continuous Glucose Monitoring (CGM) Study</brief_title>
  <official_title>PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feinberg School of Medicine, Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Providence Medical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seven-point capillary profiles have shown that mean glucose correlates with both diabetic
      retinopathy and nephropathy risk. However, there remains great controversy as to whether the
      degree of variability around mean glucose may also contribute to these microvascular
      complications. The PERL trial (NCT02017171), testing whether treatment with allopurinol can
      slow down kidney function loss in type 1 diabetes, provides a unique opportunity to assess
      the role of glycemic variability in the progression of diabetic kidney disease in individuals
      who already have mild to moderate kidney disease. By applying Continuous Glucose Monitoring
      (CGM) in the PERL Study population, the investigators will be able to better understand how
      metrics of glycemia (mean, time above and below range, and various measures of variability)
      are associated with renal outcomes in the PERL population as a whole, but also in important
      subgroups (e.g., albuminuric vs. normoalbuminuric subjects with ongoing GFR decline,
      allopurinol vs. placebo arms). The nvestigators also aim to obtain precise information on the
      range of blood glucose corresponding to any given HbA1c value in this population since
      previous studies generally excluded patients with renal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who consent to the study will have an Abbott Freestyle Libre Pro sensor placed
      on the back of their upper arm at their first PERL visit after this ancillary study has begun
      and at all subsequent PERL Visits. The sensor will be continuously worn by participants for
      14 days. At the end of the 14 days, the sensor will be removed and mailed by the participant
      to the Coordinating center. Since subjects are at various stages of the PERL protocol, the
      number of remaining visits at which the CGM will be applied will vary among subjects.

      STUDY AIMS

        1. To assess the effect of glycemic variability, as measured by the coefficient of
           variation of CGM glucose (CV, the ratio of standard deviation and the mean of CGM
           glucose values), on the PERL renal functional endpoint (iohexol GFR at the end of
           study).

        2. To assess the effect of other glycemic parameters measured by CGM (mean glucose, % time
           70-180 mg/dL, % time below 54 mg/dL, % time below 70 mg/dL, % time above 180 mg/dL, %
           time above 250 mg/dL, mean amplitude of glucose excursions [MAGE], low blood glucose
           index [LBGI], high blood glucose index [HBGI]) on the PERL renal functional endpoint.

        3. To assess the relationship between CGM-measured glycemic parameters and HbA1c at various
           levels of renal function.

        4. To compare the effects of CGM metrics on the PERL renal endpoint and the corresponding
           effect of HbA1c.

        5. To assess the effect of allopurinol treatment on all of the different glycemic metrics
           including HbA1c, CV, etc. and on their association with the PERL renal endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>iGFR at the end of the PERL trial</measure>
    <time_frame>Week 164 of the PERL trial</time_frame>
    <description>Glomerular filtration rate (GFR) at the end of the PERL trial, measured by the plasma clearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c at week 80 of the PERL trial</measure>
    <time_frame>Week 80 of the PERL Trial</time_frame>
    <description>Hba1c value at week 80 of the PERL trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at week 96 of the PERL trial</measure>
    <time_frame>Week 96 of the PERL Trial</time_frame>
    <description>Hba1c value at week 96 of the PERL trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at week 112 of the PERL trial</measure>
    <time_frame>Week 112 of the PERL Trial</time_frame>
    <description>Hba1c value at week 112 of the PERL trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at week 128 of the PERL trial</measure>
    <time_frame>Week 128 of the PERL Trial</time_frame>
    <description>Hba1c value at week 128 of the PERL trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at week 142 of the PERL trial</measure>
    <time_frame>Week 142 of the PERL Trial</time_frame>
    <description>Hba1c value at week 142 of the PERL trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at week 156 of the PERL trial</measure>
    <time_frame>Week 156 of the PERL Trial</time_frame>
    <description>Hba1c value at week 156 of the PERL trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at week 164 of the PERL trial</measure>
    <time_frame>Week 164 of the PERL Trial</time_frame>
    <description>Hba1c value at week 164 of the PERL trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Mean of blood glucose values measured by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV (coefficient of variation) of blood glucose</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Coefficient of variation of blood glucose values measured by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% time 70-180 mg/dL</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Percentage of time with blood glucose in the 70-180 mg/dL range (as measured by continuous glucose monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% time below 54 mg/dL</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Percentage of time with blood glucose below 54 mg/dL (as measured by continuous glucose monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% time above 180 mg/dL</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Percentage of time with blood glucose above 180 mg/dL (as measured by continuous glucose monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% time above 250 mg/dL</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Percentage of time with blood glucose above 250 mg/dL (as measured by continuous glucose monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAGE (Mean amplitude of glucose excursions)</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Mean amplitude of glucose excursions as measured by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBGI (Low blood glucose index)</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>Low blood glucose index based on blood glucose values measured by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGI (High blood glucose index)</measure>
    <time_frame>From week 80 to week 164 of the PERL trial</time_frame>
    <description>High blood glucose index based on blood glucose values measured by continuous glucose monitoring</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <description>Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-treated</arm_group_label>
    <description>Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mean blood glucose</intervention_name>
    <description>Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood glucose CV</intervention_name>
    <description>Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>% time 70-180 mg/dL</intervention_name>
    <description>Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>% time below 54 mg/dL</intervention_name>
    <description>Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>% time above 180 mg/dL</intervention_name>
    <description>Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>% time above 250 mg/dL</intervention_name>
    <description>Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MAGE (Mean amplitude of glucose excursions)</intervention_name>
    <description>Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LBGI (Low Blood Glucose Index)</intervention_name>
    <description>Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HBGI (High Blood Glucose Index)</intervention_name>
    <description>High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Oral allopurinol tablets administered in the PERL Clinical Trial</description>
    <arm_group_label>Allopurinol-treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo tablets administered in the PERL Clinical Trial</description>
    <arm_group_label>Placebo-treated</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants of the PERL Clinical Trial
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Being an active participant in the PERL clinical trial

        Exclusion Criteria:

          -  Having completed PERL Visit 16

          -  Pregnancy

          -  History of skin reactions in relation to the application of Abbott Freestyle Libre Pro
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Doria, MD PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irl Hirsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janet McGill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University, St. Louis, MO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center / University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University - Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brehm Center for Diabetes Research / University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine / Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICAHN School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unversity of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Diabetes</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Y 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T-3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Joslin Diabetes Center</investigator_affiliation>
    <investigator_full_name>Alessandro Doria</investigator_full_name>
    <investigator_title>Senior Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

